GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Intellia Therapeutics
Intellia is a pioneering company in the field of CRISPR gene editing. Its stock price represents a venture bet on a revolutionary technology capable of treating genetic diseases. The stock price reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Dna
Intellia is a pioneer in CRISPR gene editing, which is its only segment. We classify it as part of the DNA sector, and the chart below reflects the dynamics of this entire revolutionary and high-risk field of biotechnology.
Broad Market Index - GURU.Markets
Intellia Therapeutics is a leading CRISPR gene editing company developing treatments for genetic diseases. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Intellia is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
NTLA - Daily change in the company's share price Intellia Therapeutics
The volatility of Intellia Therapeutics, a pioneer in CRISPR genome editing, reflects the enormous promise and risks of gene therapy. Change_co is an immediate reaction to clinical trial data. This indicator forms the basis for analysis in the advanced biotech sector using System.GURU.Markets tools.
Daily change in the price of a set of shares in a market segment - Dna
Intellia Therapeutics, Inc., a pioneer in CRISPR gene editing, demonstrates the extreme volatility of the biotech sector. Comparison with NTLA, a near-zero bet on the success of this revolutionary technology, clearly demonstrates its extreme risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Intellia is a pioneering company in the field of CRISPR gene editing, one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Intellia Therapeutics
Intellia is a pioneer in the use of CRISPR genome editing technology. Its year-over-year growth is not tied to current profits, but reflects its technological progress and investors' belief in its revolutionary potential for treating genetic diseases.
Annual dynamics of market capitalization of the market segment - Dna
Intellia Therapeutics, Inc. is a leading company developing drugs based on the revolutionary CRISPR gene-editing technology. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field of biotechnology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intellia, a pioneer in the revolutionary CRISPR gene-editing technology, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Intellia Therapeutics
Intellia, a pioneer in CRISPR gene editing, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its gene therapy clinical trials, the success of which determines whether this revolutionary technology will truly realize its potential.
Monthly dynamics of market capitalization of the market segment - Dna
Intellia Therapeutics is a leading company developing drugs based on the revolutionary CRISPR gene-editing technology. Its sector performance, shown in the chart, reflects investor confidence in genomic medicine. This allows us to assess how Intellia's clinical trial progress and the potential of its platform influence industry perceptions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intellia Therapeutics is a pioneer in CRISPR genome editing. This is a revolutionary but high-risk field. The overall market has little impact on Intellia; its shares are driven by news of clinical trials, and a single successful result could trigger explosive growth, defying any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Intellia Therapeutics
Intellia Therapeutics, a pioneer in CRISPR gene editing, is experiencing extreme volatility. Weekly stock price movements reflect preclinical and clinical trial data, scientific publications, and competitor news. The chart reflects the high stakes and risks of gene therapy.
Weekly dynamics of market capitalization of the market segment - Dna
Intellia Therapeutics, like other gene-editing companies, is part of the volatile biotech sector. This chart compares its performance with the industry, showing how much of its movements are driven by general biotech sentiment and how much by the unique data from its clinical trials.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Intellia Therapeutics is a leader in CRISPR gene editing. This is a technology of the future with enormous risks. The chart below shows how Intellia shares, a highly speculative asset, move at their own pace, responding to scientific breakthroughs rather than general market sentiment.
Market capitalization of the company, segment and market as a whole
NTLA - Market capitalization of the company Intellia Therapeutics
Intellia Therapeutics' stock chart is a financial frontier of genetic engineering. Its market cap is based on faith in the revolutionary CRISPR genome editing technology, which can cure genetic diseases. Its volatility is a direct reflection of news from the lab and clinic, where every result can either confirm or undermine lofty expectations.
NTLA - Share of the company's market capitalization Intellia Therapeutics within the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR-based genome editing. Its high market capitalization reflects the enormous potential of this revolutionary technology for treating genetic diseases. The chart below shows how much the market is betting on Intellia's leadership in the race to develop next-generation drugs.
Market capitalization of the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics are a barometer of investor confidence in the potential of this revolutionary technology to treat previously incurable diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Intellia Therapeutics is a pioneer in the field of CRISPR genome editing. Its market capitalization chart is a financial reflection of one of the most revolutionary technologies in the history of biology. Its value reflects a bet that the ability to "correct" DNA will radically change the medicine of the future.
Book value capitalization of the company, segment and market as a whole
NTLA - Book value capitalization of the company Intellia Therapeutics
For Intellia Therapeutics, a pioneer in genome editing, book value is its laboratories and R&D capital. The chart below shows financial and scientific resources, not factories. Growth in this area represents investment to build the material base for future genetic medicines.
NTLA - Share of the company's book capitalization Intellia Therapeutics within the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing. The company's value lies in its intellectual property and scientific platform. The share of physical assets chart will reflect its focus on research, where its core assets are cutting-edge laboratories rather than mass production.
Market segment balance sheet capitalization - Dna
Intellia Therapeutics is a pioneer in CRISPR gene editing. Its value lies almost entirely in its intellectual property and scientific discoveries. Its book value chart shows a low proportion of tangible assets, clearly illustrating the biotech startup's business model, where its primary asset is future patents.
Book value of all companies included in the broad market index - GURU.Markets
Intellia Therapeutics' assets constitute an arsenal for genome editing. The company's book value consists of cutting-edge laboratories, sophisticated biotech equipment, and manufacturing facilities for the creation of CRISPR drugs. The chart shows the capital invested in the physical infrastructure for correcting genetic diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR genome editing. Its book value is primarily derived from cash reserves. Its market capitalization, however, reflects investor hopes that its technology will cure genetic diseases. This is a pure valuation of scientific breakthroughs, not tangible assets.
Market to book capitalization ratio in a market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing. The company's core assets are its patents and scientific developments. The chart shows the enormous premium the market places on the potential of this revolutionary technology compared to its meager tangible assets. This trend reflects confidence in future therapeutic breakthroughs.
Market to book capitalization ratio for the market as a whole
Intellia Therapeutics is a pioneer in CRISPR genome editing. The company's value lies not in its labs, but in the potential of its revolutionary technology to alter DNA to treat disease. The chart shows how its market valuation reflects investors' faith in scientific breakthroughs, creating a huge gap with its book value, which is primarily comprised of cash.
Debts of the company, segment and market as a whole
NTLA - Company debts Intellia Therapeutics
Intellia Therapeutics, a pioneer in CRISPR genome editing, is using debt to finance its revolutionary scientific platform. The chart below shows the capital raised for preclinical research and clinical trials. This represents a long-term investment in a therapy that could transform the treatment of genetic diseases.
Market segment debts - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing. For biotech companies at the forefront of science, debt is a way to finance years of research before commercializing therapies. The chart illustrates how Intellia's debt strategy compares to the high risk and potential of disruptive technologies in its sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR gene editing, a technology with enormous potential but requiring colossal investments in R&D. This chart shows the company's financial strategy. Low debt is critical for a biotech company during the research phase, as it allows it to avoid creditor pressure before the therapy is commercialized.
Market segment debt to market segment book capitalization - Dna
Intellia Therapeutics is a pioneer in CRISPR/Cas9 genome editing. This fundamental science has the potential to transform medicine, but it requires enormous investment. The chart shows the overall debt burden in the biotech sector, providing insight into how Intellia finances its revolutionary, yet very expensive and time-consuming, research.
Debt to book value of all companies in the market
Intellia Therapeutics is a pioneer in genome editing, which requires massive long-term investment. This chart shows the overall market leverage. It allows one to assess how investor risk appetite is changing and how this impacts the ability of Intellia and other cutting-edge companies to raise capital for their groundbreaking research.
P/E of the company, segment and market as a whole
P/E - Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR gene editing for treating genetic diseases. This chart reflects investors' faith in this medical revolution. Its value reflects not current revenue estimates, but rather the colossal potential of a technology that could one day cure diseases currently considered incurable, promising enormous future profits.
P/E of the market segment - Dna
Intellia Therapeutics is a pioneer in the CRISPR genome editing sector. This chart shows the average P/E for this revolutionary industry, based on future expectations. Comparing the company's P/E to this metric allows one to understand how highly the market values its development portfolio and intellectual property compared to other CRISPR companies.
P/E of the market as a whole
Intellia Therapeutics is a pioneer in CRISPR gene editing, developing treatments for genetic diseases. Its valuation is based on the technology's potential to revolutionize medicine. This chart reflects investors' risk appetite. It helps us understand whether Intellia's valuation is part of the broader biotech boom or whether it's in its own unique world of scientific discovery.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Intellia Therapeutics
Intellia Therapeutics is a leading company developing treatments based on CRISPR gene editing technology. This chart reflects investor expectations regarding the clinical success and future approval of its therapies. It is an assessment of the long-term potential of this revolutionary technology, not current financial performance.
%20P%2FE%20Intellia%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Intellia-Therapeutics&v=1772513863100 "Chart of the company's future (projected) P/E Intellia Therapeutics")
Future (projected) P/E of the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR gene editing, developing treatments for genetic diseases. This chart shows how the market views its future potential compared to other biotech companies. It reflects investor optimism regarding its clinical programs and groundbreaking scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513863165 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Intellia Therapeutics is a pioneer in developing therapeutics based on CRISPR/Cas9 gene editing technology. For a company at the forefront of science, the overall market backdrop, reflected in this chart, is critical. Investor optimism provides the capital needed to conduct lengthy and complex clinical trials that could transform medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513863205 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Intellia Therapeutics
Intellia Therapeutics is a leading company in the field of CRISPR genome editing. Its financial profile is typical for the biotech sector at the R&D stage: significant research expenses and a lack of stable revenue. This chart reflects the cost of cutting-edge scientific developments, with future profitability dependent on the success of clinical programs.
Profit of companies in the market segment - Dna
Intellia Therapeutics is a pioneer in genome editing using CRISPR/Cas9 technology. The overall profitability of the biotech sector, as seen here, is largely a bet on future breakthroughs. The success of Intellia's clinical programs could not only lead to the development of cures for previously untreatable genetic diseases but also set the direction for the entire industry.
Overall market profit
Intellia Therapeutics is a pioneer in CRISPR genome editing. The company is developing drugs that can cure genetic diseases. Its market capitalization and growth depend on scientific breakthroughs rather than traditional economic cycles. Intellia exemplifies how biotechnology creates value by solving previously unsolvable problems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR/Cas9 genome editing for the development of new treatments. The future profit expectations you see are based entirely on the potential of its therapeutic programs. These projections are highly sensitive to clinical trial results and news about progress in developing breakthrough drugs.
%20profit%20of%20the%20company%20Intellia%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Intellia-Therapeutics&v=1772513863332 "Graph of future (projected) profit of the company Intellia Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing potentially revolutionary treatments for genetic diseases. This chart reflects aggregate profitability expectations for the entire gene therapy industry, demonstrating the financial prospects analysts see for this cutting-edge, yet not yet fully commercialized, field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513863340 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Intellia Therapeutics is a pioneer in CRISPR genome editing. For a company working to develop revolutionary treatments, clinical success is more important than current economic cycles. However, the overall profit outlook reflected here impacts investor risk appetite and the valuation of the entire biotech sector, which affects Intellia's access to capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513863341 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing treatments for genetic diseases. For a company whose technology promises to revolutionize medicine, this chart is invaluable. It reflects not current sales estimates, but rather investors' confidence in the future commercial success of its platform, which is reflected in a high valuation of even the smallest revenues.
P/S market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing potential therapeutics for genetic diseases. The company's value lies in its revolutionary scientific platform. This chart reflects investor revenue expectations for the gene therapy sector, providing insight into how highly the market values Intellia's scientific potential and development pipeline.
P/S of the market as a whole
Intellia Therapeutics is a pioneer in CRISPR/Cas9 genome editing, developing treatments for genetic diseases. The company's valuation is based on the enormous potential of its therapeutic platform. This chart, showing average revenue estimates, highlights how much investors are willing to pay for future scientific breakthroughs compared to current financial results.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR/Cas9 genome editing for drug discovery. For a company at the forefront of science, this chart shows the market's assessment of its potential future revenue from therapies. It reflects investor confidence in the success of clinical trials and the commercial potential of this revolutionary genetic engineering technology.
%20P%2FS%20Intellia%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Intellia-Therapeutics&v=1772513863413 "The graph of the company's future (projected) P/S Intellia Therapeutics")
Future (projected) P/S of the market segment - Dna
Intellia Therapeutics is a pioneer in developing therapeutics based on CRISPR/Cas9 gene editing technology. This figure reflects its estimated future revenue relative to other biotech companies. A higher estimate indicates high expectations for its platform, while a more conservative estimate indicates high risks and a long time to commercialization.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513863423 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing treatments for genetic diseases. The company's future revenue depends on the success of clinical trials. This market expectations chart is important because it demonstrates the overall investor appetite for revolutionary, yet risky, biotech platforms.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513863431 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Intellia Therapeutics
Intellia Therapeutics, a pioneer in CRISPR genome editing, currently has revenue unrelated to drug sales. This chart reflects revenue from strategic alliances with major pharmaceutical companies. This growth reflects milestone payments for research achievements, validating the value of its revolutionary technology.
Sales of companies in the market segment - Dna
Intellia Therapeutics is a leading CRISPR genome editing company developing potential treatments for genetic diseases. It is at the forefront of biotechnology. This chart shows the overall revenue of the biotech industry, illustrating the commercial potential of the market that Intellia aims to capture with its breakthrough technologies.
Overall market sales
Intellia Therapeutics is a pioneer in CRISPR gene editing. The company's success depends on scientific breakthroughs and biotechnology investments. Its activities are not tied to everyday consumer spending, but the overall economic environment, illustrated in this chart, drives investment appetite for risky but potentially revolutionary projects that require significant capital.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Intellia Therapeutics
Intellia Therapeutics is a biotech company using revolutionary CRISPR gene editing technology to create drugs. Its revenues are currently minimal. This chart represents a long-term forecast, reflecting analysts' belief in the company's platform's enormous potential for treating previously untreatable genetic diseases.
%20sales%20of%20the%20company%20Intellia%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Intellia-Therapeutics&v=1772513863694 "Schedule of future (projected) sales of the company Intellia Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Intellia Therapeutics is a leader in CRISPR/Cas9 genome editing for drug discovery. As the company is in the clinical stage, this chart reflects the projected potential of its therapeutic programs. The data segments expectations for various drugs in development, showing which analysts consider the most promising.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513863743 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
This chart, reflecting economic sentiment, is critically important for Intellia Therapeutics. The company is developing genome editing to treat diseases. Its success depends on an influx of venture capital and partnerships with major pharmaceutical companies, and investment activity in biotech directly correlates with overall economic expectations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513863817 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR-based genome editing. This graph reflects a typical biotech R&D scenario: the company is investing in breakthrough science. Future profitability depends entirely on the success of clinical programs and the ability to commercialize treatments that can cure genetic diseases.
Market segment marginality - Dna
Intellia Therapeutics is a leading company developing therapeutics based on the revolutionary CRISPR gene-editing technology. Its future profitability depends on the success of clinical trials and the commercialization of gene therapy. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing Intellia's enormous, yet risky, potential.
Market marginality as a whole
Intellia Therapeutics is a pioneer in CRISPR genome editing. Like many research-stage biotech companies, its market cap depends on investor confidence in the technology. This chart shows the overall market risk appetite. During periods of economic growth, investors are more inclined to invest in revolutionary but long-term scientific projects.
Employees in the company, segment and market as a whole
Number of employees in the company Intellia Therapeutics
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing drugs based on this technology. This chart reflects the size of its team of leading scientists and researchers. This growth reflects progress in developing and advancing therapeutic programs to the clinic, a key indicator of success for a biotech company at the forefront of science.
Share of the company's employees Intellia Therapeutics within the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing drugs to treat genetic diseases. Its greatest asset is its world-class scientists. The graph below shows Intellia's share of all specialists in the revolutionary field of gene therapy. This demonstrates its leadership in one of the most promising areas of biotech.
Number of employees in the market segment - Dna
Intellia Therapeutics is a pioneer in developing potential therapeutics using CRISPR genome editing technology. This chart shows employment in the cutting-edge genetic engineering sector. The growing number of geneticists and bioinformaticians indicates accelerated research and clinical trials, a key success factor for an innovative company like Intellia.
Number of employees in the market as a whole
Intellia Therapeutics is a pioneer in CRISPR genome editing. Their success depends on scientific discoveries and advances in the treatment of genetic diseases. This chart reflects macroeconomics, but Intellia operates in a world where capital and talent are attracted to scientific breakthroughs. Their team grows as developments move from the lab to clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Intellia Therapeutics (NTLA)
Intellia Therapeutics is a pioneer in CRISPR gene editing. The company's value is based almost entirely on its revolutionary technology and patent portfolio. This chart shows how investors evaluate the potential of its science. A small team of elite scientists is creating intellectual property with the potential to transform medicine.
%20of%20the%20company%20Intellia%20Therapeutics%20(NTLA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Intellia-Therapeutics-NTLA&v=1772513864105 "Chart of market capitalization per employee (in thousands of dollars) of the company Intellia Therapeutics (NTLA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Intellia Therapeutics is a pioneer in CRISPR genome editing. They develop treatments by editing genes directly in the body. This is pure R&D and intellectual property. The market value of such companies is based on the potential of their therapeutic platform, not on their staff. This indicator reflects a high IP per employee.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513864111 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Intellia Therapeutics is a pioneer in CRISPR genome editing, developing drugs to treat genetic diseases. The company's market capitalization is based on the revolutionary potential of its scientific platform. This metric demonstrates its exceptionally high cost per employee, as a small group of scientists possesses technology capable of transforming medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513864136 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Intellia Therapeutics (NTLA)
Intellia Therapeutics is a pioneer in the field of CRISPR genome editing. Their employees are the world's leading scientists, working on drugs that can treat genetic diseases at the DNA level. This chart doesn't show profit, but rather the net cost of R&D per scientist literally trying to rewrite the code of life.
%20Chart%20Intellia%20Therapeutics%20(NTLA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Intellia-Therapeutics-NTLA&v=1772513864175 "Company Profit Per Employee (in thousands of dollars) Chart Intellia Therapeutics (NTLA)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Intellia is a pioneer in *gene therapy*, using CRISPR/Cas9 technology. This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through R&D (clinical trials) money, trying to create a "revolutionary drug."
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513864197 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Intellia Therapeutics is a pioneer in the field of CRISPR genome editing. They don't just treat diseases; they aim to "correct" them at the DNA level. This cutting-edge science requires enormous R&D resources and elite biologists. This chart demonstrates how radically the biotech model, where a few scientists can transform medicine, differs from the average per-worker profitability in the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513864247 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Intellia Therapeutics (NTLA)
Intellia Therapeutics is a pioneer in CRISPR genome editing. Like many research-stage biotechs, the company's commercial revenue per employee is minimal. The chart shows revenue from strategic partnerships, and its primary value lies in the future, when approved treatments begin generating revenue, reflecting breakthrough potential.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Intellia-Therapeutics-NTLA&v=1772513864257 "Sales chart per company employee Intellia Therapeutics (NTLA)")
Sales per employee in the market segment - Dna
Intellia is a pioneer in the field of CRISPR/Cas9 genome editing. This fundamental science is aimed at creating cures for genetic diseases. The company does not yet have any commercial products. This chart illustrates that the productivity of their elite team of scientists is currently measured not by sales, but by progress in clinical trials, which generates future value.
Sales per employee for the market as a whole
Intellia Therapeutics (NTLA) is a pioneer in CRISPR genome editing, developing drugs to treat genetic diseases. The company is in the clinical stage, meaning its revenue (if any) comes from partnerships rather than sales. This chart illustrates the economics of R&D, showing how much capital the company is investing in its world-class scientists to create therapies of the future.
Short shares by company, segment and market as a whole
Shares shorted by company Intellia Therapeutics (NTLA)
Intellia Therapeutics is a pioneer in CRISPR/Cas9 gene editing. It's a technology with enormous potential, but also enormous risks. This chart shows the level of skepticism. Bears are betting on long-term safety risks for CRISPR, potential failures in clinical trials, or that competitors (like Editas or CRISPR Therapeutics) will get there first.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Intellia-Therapeutics-NTLA&v=1772513864447 "Short Shares Chart for the Company Intellia Therapeutics (NTLA)")
Shares shorted by market segment - Dna
Intellia Therapeutics (NTLA) is a pioneer in the field of CRISPR genome editing. They are developing treatments for genetic diseases by repairing DNA. This chart shows the overall sentiment in the gene therapy sector. Investors shorting this disruptive industry are likely concerned about high development costs, the long road to commercialization, or regulatory hurdles.
Shares shorted by the overall market
Intellia (NTLA) is a pioneer in gene editing (CRISPR). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives NTLA of capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Intellia Therapeutics (NTLA)
Intellia Therapeutics is a pioneer in the revolutionary CRISPR genome editing technology. It's a clear bet on a breakthrough in medicine. This chart measures the level of hope and fear. It shows when the stock is "overbought" on enthusiastic early trial data or "oversold" on concerns about safety and long-term effects.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Intellia-Therapeutics-NTLA&v=1772513864541 "RSI 14 indicator chart for the company's stock Intellia Therapeutics (NTLA)")
RSI 14 Market Segment - Dna
Intellia Therapeutics is a pioneer in the field of genome editing. The company uses CRISPR (genetic "scissors") technology to develop drugs that can directly correct genes in the body. This chart measures the collective excitement in the gene therapy sector. It helps us understand whether the entire speculative segment is overheated by expectations of a breakthrough.
RSI 14 for the overall market
Intellia (NTLA), a company engaged in "genome editing," is its lifeline. This graph is its lifeline. Its business is pure R&D. In times of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and NTLA risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NTLA (Intellia Therapeutics)
Intellia Therapeutics is a pioneer in the field of CRISPR genome editing. The company develops treatments for genetic diseases by repairing DNA. This chart shows the average target price. Analysts' forecasts are based on the likelihood of clinical trial success and the market potential of this revolutionary technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NTLA-Intellia-Therapeutics&v=1772513864613 "A chart showing analyst consensus forecasts for the expected stock price. NTLA (Intellia Therapeutics)")
The difference between the consensus estimate and the actual stock price NTLA (Intellia Therapeutics)
Intellia Therapeutics (NTLA) is a pioneer in CRISPR gene editing, specializing in in vivo therapies (editing genes directly in the body). This is a pure R&D bet. This chart shows analysts' assessment of their science. It measures the gap between the price and the consensus target, reflecting the enormous, but long-term, potential they see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NTLA-Intellia-Therapeutics&v=1772513864629 "A chart showing the difference between the consensus forecast and the actual stock price. NTLA (Intellia Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Intellia Therapeutics is a leading company in the field of CRISPR/Cas9 genome editing. It was the first to demonstrate the feasibility of gene editing directly within the human body (in vivo). This chart shows general expectations for the DNA technology sector. It reflects whether experts believe CRISPR will become a viable drug.
Analysts' consensus forecast for the overall market share price
Intellia Therapeutics (NTLA) is a gene editor. They are a pioneer of CRISPR (like CRISPR, Editas), attempting to cure diseases both internally (in vivo) and externally (ex vivo). This chart, reflecting expert expectations, is a measure of risk appetite for them. During a downturn (pessimism), investors flee cash-burning research projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Intellia Therapeutics
Intellia is a leader in the revolutionary CRISPR gene editing technology. They focus on in vivo (editing within the body) and ex vivo (outside the body) therapies. This chart is a pure indicator of their scientific platform. It does not reflect revenue, but rather an aggregated assessment of their clinical data, the value of their R&D pipeline, and the potential of the overall CRISPR technology.
AKIMA Market Segment Index - Dna
Intellia (NTLA) is a biotech leader and a pioneer in CRISPR gene editing; the company develops breakthrough treatments for rare genetic diseases by editing DNA inside the body. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this revolutionary (CRISPR) R&D platform (NTLA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Intellia Therapeutics is a biotech company using CRISPR technology to develop treatments for genetic diseases in vivo (within the body). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this cutting-edge scientific story compares to broader economic trends that influence investor risk appetite.
